Kevin Bielamowicz, Peter Dimitrion, Oussama Abla, Simon Bomken, Patrick Campbell, Matthew Collin, Barbara Degar, Eli L Diamond, Olive S Eckstein, Nader El-Mallawany, Mark Fluchel, Gaurav Goyal, Michael M Henry, Michelle Hermiston, Michael Hogarty, Michael Jeng, Rima Jubran, Joseph Lubega, Ashish Kumar, Stephan Ladisch, Kenneth L McClain, Miriam Merad, Qing-Sheng Mi, D Williams Parsons, Erin Peckham-Gregory, Jennifer Picarsic, Zachary D Prudowsky, Barrett J Rollins, Peter H Shaw, Birte Wistinghausen, Carlos Rodriguez-Galindo, Carl E Allen
Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations range from single lesions with minimal impact to life-threatening disseminated disease. Therapy for systemic LCH has been established through serial trials empirically testing different chemotherapy agents and durations of therapy. However, fewer than 50% of patients who have disseminated disease are cured with the current standard-of-care vinblastine/prednisone/(mercaptopurine), and treatment failure is associated with long-term morbidity, including the risk of LCH-associated neurodegeneration...
April 30, 2024: Cancer